Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2006-10-17
2006-10-17
Nazario-Gonzalez, Porfirio (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C546S002000, C548S101000, C556S137000, C514S492000
Reexamination Certificate
active
07122668
ABSTRACT:
The present invention concerns novel platinum complexes in which at least one of the amine ligand is a non-planar heterocyclic aliphatic amine. The platinum complexes may be in a trans or cis configuration and were found to posses therapeutic activites. Thus, the present concerns novel platinum complexes, pharmaceutical compositions comprising them and other uses thereof.
REFERENCES:
patent: 4902797 (1990-02-01), Totani et al.
patent: 5026694 (1991-06-01), Skov et al.
patent: 2004/0097423 (2004-05-01), Siddik et al.
patent: 0 273 315 (1988-07-01), None
patent: 0727 430 (1996-08-01), None
Belluco et al., Necleophilic Constants and Substrate Discrimination Factors for Substitution Reactions of Platinum(II) Complexes, Journal of American Chemical Society, vol. 87, No. 2, pp. 241-246 (1965).
Jamieson, E.R., et al, “Structure, Recognition, and Processing of Cisplatin-DNA Adducts”,Chem. Rev., pp. 2467-2498, (1999).
Kartalou, M., et al., “Recognition Of Cisplatin Adducts By Cellular Proteins”,Mutation Research, pp. 1-21, (2001).
Gonzalez, V.M., et al., “Is Cisplatin-Induced Cell Death Always Produced By Apoptosis?”Molecular Pharmacology, vol. 59, No. 4, pp. 657-663, (2001).
Kartalou, M., et al., “Mechanisms of resistance to cisplatin”,Mutation Research, pp. 23-43, (2001).
Cornelison, T.L.,et al., “Nephrotoxicity And Hydration Management For Cisplatin, Carboplatin, And Ormaplatin”,Gynecologic Oncology, pp. 147-158, (1993).
Wong, E., et al., “Current Status Of Platinum-Based Antitumor Drugs”,Chem. Rev. pp. 2451-2466, (1999).
Cleare, M. J., et al., “Studies On The Antitumor Activity Of Group VIII Transition Metal Complexes. Part I. Platinum (II) Complexes”,Bioinorganic Chemistry, pp. 187-210, (1973).
Bierbach, U., et al., “Synthesis, Structure, Biological Activity, and DNA Binding of Platinum (II) Complexes of the Type trans- [PtCl2(NH3) L] (L= Planar Nitrogen Base) . Effect of L and Cis/Trans Isomerism on Sequence Specificity and Unwinding Properties Observed in Globally Platinated DNA”,Inorg. Chem, pp. 3535-3542, (1999).
Montero, E.I., et al., “Preparation and Characterization of Novel trans- [PtCl2(amine) (isopropylamine) ] Compounds: Cytotoxic Activity and Apoptosis Induction in ras-Transformed Cells”,J. Med. Chem. pp. 4264-4268, (1999).
Coluccia, M., et al., “In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands”,Journal of Inorganic Biochemistry, pp. 31-35, (1999).
Roberts, J.D., et al., “Cellular pharmacology of polynuclear platinum anti-cancer agents”,Journal of Inorganic Biochemistry, pp. 51-57, (1999).
Kelland, L.R., et al., “Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance”,Journal of Inorganic Biochemistry, pp. 111-115, (1999).
Bierbach, U., et al., “Inversion of the Cis Geometry Requirement for Cytotoxicity in Structurally Novel Platinum (II) Complexes Containing the Bidentate N, O-Donor Pyridin-2-yl-acetate”,Inorganic Chem, pp. 1882-1890, (2000).
Hollis, L.S., et al., Chemical and Biological Properties of a New Series of cis-Diammineplatinum (II) Antitumor Agents Containing Three Nitrogen Donors: cis- [Pt (NH3)2(N-donor) Cl]+,J. Med. Chem., pp. 128-136, (1989).
Kelland, L.R., et al., “Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV) : an orally active platinum drug”,Cancer Research, pp. 2581-2586, (1993).
Loh, S.Y., et al., “Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes”,Brit.J. Cancer, pp. 1109-1115, (1992) .
Goddard, P.M., et al, “ Novel Trans Platinum Complexes: Comparativein Vitroandin VivoActivity Against Platinum-Sensitive and Resistant Murine Tumours”,Anticancer Research, pp. 33-38, (1996).
Behrens, B.C., et al., “Characterization of a cisdiammine-dichloroplatinum (II) -resistant human ovarian cancer cell line and its use in evaluation of platinum analogues”,Cancer Research, pp. 414-418, (1987).
Gorodetsky, R., et al., “Combination of cisplatin and radiation in cell culture: Effect of duration of exposure to drug and timing of irradiation”,Int. J. Cancer, pp. 635-642, (1998).
Gorodetsky, R., et al., “Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines”,Israel J. Med. Science, pp. 95-100, (1995).
Cory, A.H., et al., “Use of an Aqueous Soluble Tetrazolium/Formazan Assay for Cell Growth Assays in Culture”,Cancer Communications, pp. 207-212, (1991).
Lindauer, E., et al., “Cellular Distribution and Cellular Reactivity of Platinum (II) Complexes”,Biochemical Pharmacology, pp. 7-14, (1996).
Zuidam, N., et al., “Lamellarity of cationic liposomes and mode of preparation of lipoplexes affect transfection efficiency”,Biochimica ET Biophysica Acta, pp. 207-220, (1999).
Chen, S.E., et al., “DOTAP cationic liposomes prefer relaxed over supercoiled plasmids”,Biochimica ET Biopysica Acta, pp. 176-188, (2000).
Reid, S., et al., “Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage, viability and apoptosis”,Journal of Immunological Methods, pp. 43-54, (1996).
Holford, J., et al., “Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex,cis- [amminedichloro (2-methylpyridine) ] platinum (II) (AMD473)”,Anti-Cancer Drug Design, pp. 1-18, (1998).
Thornberry, N.A, et al., “Caspases: Enemies Within”,Science, pp. 1312-1316, (1998).
Villa, P., et al., “Caspases and caspase inhibitors”,Science, pp. 388-393, (1997).
Ciesielska, E., et al., “Dna Damage And Apoptosis Induction In L1210 Cells ByCis-Diamminedichloroplatinum (II) And Its New Aminoflavone Analogue”Cellular&Molecular Biology Letters, pp. 441-450, (2000).
Lui, W., et al., “Endothelial Cell Apoptosis Is Inhibited By A Soluble Factor Secreted By Human Colon Cancer Cells”,Int. J. Cancer, pp. 26-30, (2001).
Barenholz, Y., et al., “Quality Control Assays In The Development And Clinical Use Of Liposome-Based Formulations”, 2ndEd., G. Gregoriadis (Ed.)CRC Press, Boca Raton, Ch.29, vol. 1, pp. 527-616, (1993).
XP-001117912: Nguyen, H., et al, “1H-NMR Spectra And Structure Of Some Pt (II)—Complexes Containing Quinoline”,Vietnam Journal of Chemistry, vol. 39 No. 4, pp. 111-114, (2001).
XP-001119544: Tran, T., et al., “Synthesis and Biological Effects of some complex cis-diamine Compounds of Platinum (II) containing Piperidine or Morpholine and some other Amines”,Tap Chi Duoc Hoc, No. 6, pp. 6-8, (2001).
XP 001117911: Tran, T., et al., “syntheses and properties of some mixed cis-diamine pt(II) complexes containing piperidine and aromatic amines”,Vietnam Journal of Chemistry, vol. 39, No. 3, pp. 99-102, (2001).
XP-001119543: Tran T., et al., “synthesis and properties of some mixed cis-diamine of platinum (II) containing quinoline”,Vietnam Journal of Chemistry, vol. 35, No. 2, pp. 21-23, (1997).
XP-001119659: Ivanova, N., et al., “Coordination Abilities Of Piperazine In Platinum (II), Platinum (IV), And Palladium (II) Complexes”,Russian Journal of Coordination Chemistry, vol. 19, No. 12, pp. 856-863, (1993).
XP-001119636: Cattalini, L, et al., “The cis-and trans-Effects of Cyanide in Substitutuion at Platinum (II)”,Journal of the Chemical Society, Dalton Transactions, pp. 233-236, (1993).
XP-002220406: Wong, E., et al., “Current Status of Platinum-Based Antitumor Drugs”,Chem. Rev., pp. 2451-2466, (1999).
Barenholz Yechezkel
Gibson Dan
Khazanov Elena
Najajreh Yousef
Hopkins Susanne M.
Nath Gary M.
nath & Associates PLLC
Nazario-Gonzalez Porfirio
Yissum Research Development Company of the Hebrew University of
LandOfFree
Platinum complexes and their use in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platinum complexes and their use in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platinum complexes and their use in therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679761